CNS neuroscience & therapeutics · 2025
The Progression of NUS1-Associated Parkinson's Disease and the Diagnostic Potential of Plasma NgBR.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Li Lizhi, Huang Juanjuan, Xiang Yaqin, Zhang Xuxiang, Xu Qian, Sun Qiying, Liu Zhenhua, Yan Xinxiang, Li Jinchen, Tang Beisha, Guo Jifeng
Аннотация
AIMS: The study aimed to investigate the role of NUS1 variants in Parkinson's disease (PD) progression and evaluate plasma Nogo-B receptor (NgBR) as a potential biomarker.
METHODS: We recruited 228 PD patients, including 38 with NUS1 variants (NUS1-PD) and 190 without (GU-PD), and all underwent at least two follow-up visits. Linear mixed-effects models assessed motor and non-motor symptom progression. Plasma NgBR levels were measured in PD, Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and healthy controls (HC), and receiver operating characteristic curve analysis evaluated its diagnostic efficacy.
RESULTS: NUS1-PD demonstrated an earlier age at onset and more severe motor features than GU-PD at baseline. Longitudinal analyses showed similar progression rates of UPDRS III and H&Y stage (off-medication) in NUS1-PD and GU-PD, but a slower progression rate of urinary function in NUS1-PD (p = 0.024). Plasma NgBR levels were higher in PD than in HC, MSA, and PSP, with AUC values of 0.6832, 0.6716, and 0.6628, respectively. Plasma NgBR was associated with UPDRS III (p = 0.006) and cognitive impairment (p = 0.010).
CONCLUSION: NUS1 variants show no impact on PD progression, while plasma NgBR may serve as a potential biomarker for PD diagnosis and clinical characteristics.
METHODS: We recruited 228 PD patients, including 38 with NUS1 variants (NUS1-PD) and 190 without (GU-PD), and all underwent at least two follow-up visits. Linear mixed-effects models assessed motor and non-motor symptom progression. Plasma NgBR levels were measured in PD, Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP), and healthy controls (HC), and receiver operating characteristic curve analysis evaluated its diagnostic efficacy.
RESULTS: NUS1-PD demonstrated an earlier age at onset and more severe motor features than GU-PD at baseline. Longitudinal analyses showed similar progression rates of UPDRS III and H&Y stage (off-medication) in NUS1-PD and GU-PD, but a slower progression rate of urinary function in NUS1-PD (p = 0.024). Plasma NgBR levels were higher in PD than in HC, MSA, and PSP, with AUC values of 0.6832, 0.6716, and 0.6628, respectively. Plasma NgBR was associated with UPDRS III (p = 0.006) and cognitive impairment (p = 0.010).
CONCLUSION: NUS1 variants show no impact on PD progression, while plasma NgBR may serve as a potential biomarker for PD diagnosis and clinical characteristics.